

Kentaro Watai, MD, PhD, presented a comprehensive genetic and nutritional study from Japan, aiming to uncover the hidden biological signatures of Multiple Chemical Sensitivity (MCS). By using advanced genomic tools to look at the entire human genome, Dr. Watai's presentation demonstrated that MCS is a complex, multi-system condition that goes far beyond simple issues with how the body processes alcohol or toxins.

One of the most significant parts of the presentation was the Genome-Wide Association Study (GWAS), which compared the DNA of hundreds of Japanese MCS patients with a large control group. The study used the Japonica Array, a genetic tool specifically optimized for the Japanese population. Dr. Watai's team identified a highly suggestive genetic marker near the RBM3 gene. This gene is biologically fascinating because it is linked to the regulation of inflammation and the immune system. Finding a signal in this area suggests that MCS may involve a specialized type of neuro-immune sensitivity, where the nervous system and immune system are genetically primed to overreact to environmental triggers.

Dr. Watai also explored the interesting link between alcohol intolerance and MCS. Many people with MCS report they cannot tolerate alcohol, and while some of this is due to a well-known protein called ALDH2, Dr. Watai's research found other genetic markers that seem to link alcohol intolerance with broader chemical reactivity. This suggests that for many patients, alcohol intolerance isn't just a separate problem; it's a clinical marker for a system that is generally hypersensitive to many different types of chemical exposures.

Ultimately, Dr. Watai's presentation provides a vital piece of the scientific puzzle for the MCS community. It moves the conversation toward a model of neuro-immune sensitivity. His work shows that the biological roots of MCS are deep and complex, involving a delicate interplay between our genetic blueprint and our immune system's ability to stay in balance. This research reinforces the legitimacy of MCS as a physical condition that requires sophisticated, science-based management and treatment methods.

References

- Badrani, J. H., Strohm, A. N., Lacasa, L., Civello, B., Cavagnero, K., Haung, Y. A., Amadeo, M., Naji, L. H., Lund, S. J., Leng, A., Kim, H., Baum, R. E., Khorram, N., Mondal, M., Seumois, G., Pilotte, J., Vanderklish, P. W., McGee, H. M., & Doherty, T. A. (2022). RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R. *Nature communications*, 13(1), 4435. <https://doi.org/10.1038/s41467-022-32176-5>
- Watai, K., Ochi, S., Matsuura, T., & Azuma, K. (2026). Comparison of serum 25-hydroxyvitamin D levels between patients with multiple chemical sensitivity and healthy controls: A case-control study. *Scientific reports*, 16(1), 13943. <https://doi.org/10.1038/s41598-026-44643-w>